{"id":7521,"date":"2024-06-28T14:35:56","date_gmt":"2024-06-28T05:35:56","guid":{"rendered":"https:\/\/abionbio.com\/en\/?p=7521"},"modified":"2024-11-08T15:02:02","modified_gmt":"2024-11-08T06:02:02","slug":"abion-signed-agreement-with-johnson-johnson-on-drug-supply-for-combination-clinical-trial","status":"publish","type":"post","link":"https:\/\/abionbio.com\/en\/2024\/06\/28\/abion-signed-agreement-with-johnson-johnson-on-drug-supply-for-combination-clinical-trial\/","title":{"rendered":"Abion signed agreement with Johnson &#038; Johnson on drug supply for combination clinical trial"},"content":{"rendered":"<p>Abion and Janssen Research and Development, LLC, a Johnson &amp; Johnson company have entered into a drug supply agreement to advance a combination clinical trial targeting EGFR-mutated non-small cell lung cancer (NSCLC).<br \/>\nThe trial will investigate the efficacy of ABN401 (vabametkib), Abion&#8217;s c-MET inhibitor, in combination with Johnson &amp; Johnson\u2019s EGFR inhibitor, lazertinib. This collaboration aims to address resistance in patients with NSCLC that arises due to c-MET alterations.<br \/>\nUnder this agreement, Abion will act as the sponsor of the clinical study, while Johnson &amp; Johnson will provide lazertinib at no cost to support the trial.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Abion and Janssen Research and Development, LLC, a Johnson &amp; Johnson company have entered into&#8230;<\/p>\n","protected":false},"author":2,"featured_media":6908,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[],"class_list":{"0":"post-7521","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-press-release"},"_links":{"self":[{"href":"https:\/\/abionbio.com\/en\/wp-json\/wp\/v2\/posts\/7521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/abionbio.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/abionbio.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/abionbio.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/abionbio.com\/en\/wp-json\/wp\/v2\/comments?post=7521"}],"version-history":[{"count":1,"href":"https:\/\/abionbio.com\/en\/wp-json\/wp\/v2\/posts\/7521\/revisions"}],"predecessor-version":[{"id":7523,"href":"https:\/\/abionbio.com\/en\/wp-json\/wp\/v2\/posts\/7521\/revisions\/7523"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/abionbio.com\/en\/wp-json\/wp\/v2\/media\/6908"}],"wp:attachment":[{"href":"https:\/\/abionbio.com\/en\/wp-json\/wp\/v2\/media?parent=7521"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/abionbio.com\/en\/wp-json\/wp\/v2\/categories?post=7521"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/abionbio.com\/en\/wp-json\/wp\/v2\/tags?post=7521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}